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Abstract
Here, we developed an isogenic cell model of “stemness” to facilitate protein
biomarker discovery in breast cancer. For this purpose, we used knowledge gained
previously from the study of the mouse mammary tumor virus (MMTV). MMTV
initiates mammary tumorigenesis in mice by promoter insertion adjacent to two
main integration sites, namely Int-1 (Wnt1) and Int-2 (Fgf3), which ultimately
activates Wnt/β-catenin signaling, driving the propagation of mammary cancer
stem cells (CSCs). Thus, to develop a humanized model of MMTV signaling, we overexpressed WNT1 and FGF3 in MCF7 cells, an ER(+) human breast cancer cell line.
We then validated that MCF7 cells over-expressing both WNT1 and FGF3 show a 3.5fold increase in mammosphere formation, and that conditioned media from these
cells is also sufficient to promote stem cell activity in untransfected parental MCF7
and T47D cells, as WNT1 and FGF3 are secreted factors. Proteomic analysis of this
model system revealed the induction of i) EMT markers, ii) mitochondrial proteins, iii)
glycolytic enzymes and iv) protein synthesis machinery, consistent with an anabolic
CSC phenotype. MitoTracker staining validated the expected WNT1/FGF3-induced
increase in mitochondrial mass and activity, which presumably reflects increased
mitochondrial biogenesis. Importantly, many of the proteins that were up-regulated
by WNT/FGF-signaling in MCF7 cells, were also transcriptionally over-expressed in
human breast cancer cells in vivo, based on the bioinformatic analysis of public gene
expression datasets of laser-captured patient samples. As such, this isogenic cell
model should accelerate the discovery of new biomarkers to predict clinical outcome
in breast cancer, facilitating the development of personalized medicine.
Finally, we used mitochondrial mass as a surrogate marker for increased
mitochondrial biogenesis in untransfected MCF7 cells. As predicted, metabolic
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fractionation of parental MCF7 cells, via MitoTracker staining, indicated that high
mitochondrial mass is a new metabolic biomarker for the enrichment of anabolic
CSCs, as functionally assessed by mammosphere-forming activity. This observation
has broad implications for understanding the role of mitochondrial biogenesis in the
propagation of stem-like cancer cells. Technically, this general metabolic approach
could be applied to any cancer type, to identify and target the mitochondrial-rich CSC
population.
The implications of our work for understanding the role of mitochondrial
metabolism in viral oncogenesis driven by random promoter insertions are also
discussed, in the context of MMTV and ALV infections.

Introduction

fractionation by flow-cytometry.

The mouse mammary tumor virus (MMTV) is a
saliva- and milk-transmitted retrovirus [1-5]; however,
infected mice only develop mammary tumors in adulthood
[4]. This long latency period makes MMTV an interesting
virus for understanding the pathogenesis of human
breast cancers [6]. The provirus inserts upstream of
two key integration sites, named Int-1 and Int-2 [7-10].
This process of insertional mutatgenesis is thought to
be random, but involves the positive selection of genes
that will ultimately provide an increase in “stemness”,
a cellular growth-advantage, or perhaps both. MMTV
tumors are oligo-clonal, suggesting that there is some
synergy between these two different integration sites.
These mammary proto-oncogenes Int-1 and Int-2 have
been identified as WNT1 and FGF3 [11-13], two secreted
growth factors normally involved in stem cell signaling
pathways.
WNT1 is the first member of the WNT gene family,
which is known to be involved in cell fate determination
and patterning during embryogenesis [14, 15]. FGF3 is
a member of the fibroblast growth factor family, which
controls cell proliferation, morphogenesis and tissue
repair [16]. Interestingly, WNT1 and FGF3 converge
directly upon the WNT/β-catenin signaling cascade [17,
18]. However, it remains largely unknown exactly how
WNT1/FGF3 signaling induces mammary tumorigenesis.
Here, we have created a humanized model of
MMTV signaling, by over-expressing WNT1 and FGF3
in human breast cancer cells, namely MCF7 cells, an
ER(+) cell line. Unbiased label-free proteomic analysis of
this model system reveals the induction of EMT markers,
mitochondrial proteins, glycolytic enzymes and protein
synthesis machinery, consistent with an anabolic CSC
phenotype. The proteins that were up-regulated by WNT/
FGF-signaling in MCF7 cells, were also transcriptionally
over-expressed in human breast cancer cells in vivo. This
isogenic cell model should accelerate the identification
and development of new protein biomarkers to predict
clinical outcomes in breast cancer patients.
Finally, we also show that mitochondrial mass
is a new metabolic biomarker for anabolic CSCs, as
assessed by MitoTracker vital-staining and metabolic cell

Results
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Generating a humanized model of MMTV
signaling.
During MMTV infection of mammary epithelial
cells, genomic viral integration occurs. This ultimately
leads to mammary tumorigenesis in mice. Mechanistically,

Figure 1: Creating a humanized experimental model
for MMTV: Focus on WNT1 and FGF3 signaling.

To create a humanized model of MMTV signaling, we
recombinantly over-expressed WNT1 and FGF3 in MCF7 cells,
an ER(+) human breast cancer cell line. WNT1 and FGF3 were
expressed either individually or in combination, using lenti-viral
vectors carrying two different selection markers (puromycin
or neomycin/G418). This isogenic cell model of “stemness”
was generated to facilitate protein biomarker discovery in
breast cancer, via unbiased label-free proteomics. Importantly,
over-expression of FGF3, WNT1, or WNT1/FGF3 increases
mammosphere formation by 1.5-, 2.5- and 3.5-fold, respectively
(See Figure 2). Thus, we focused on MCF7-WNT1/FGF3 cells
for further validation and proteomic analysis.
30454
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the MMTV virus uses a promoter insertion mechanism of
mutagenesis, to drive oncogenesis [19]. More specifically,
the MMTV promoter inserts upstream of two main
integration sites, namely Int-1 (Wnt1) or Int-2 (Fgf3),
although a few other rare integration sites have been
described [11-13, 20] (Table 1). As a consequence, the
MMTV promoter drives the over-expression of these
secreted stem cell associated growth factors, constitutively
activating Wnt/β-catenin signaling [11, 21, 22]. Thus, the
MMTV model has been instrumental for understanding
how “amplified” or “constitutive” stem cell signaling
directly contributes to solid tumor formation (Figure 1).
As such, it would be beneficial to create a humanized
non-infectious model of MMTV signaling, to drive
the discovery of new stem cell associated biomarkers,
for predicting clinical outcome in human breast cancer

patients.
Thus, in order to create a humanized model of
MMTV signaling, we recombinantly over-expressed
WNT1 and FGF3 in MCF7 cells, an ER(+) human breast
cancer cell line. WNT1 and FGF3 were expressed either
individually or in combination, using lentiviral vectors
carrying two different selection markers (puromycin or
neomycin/G418). For comparison purposes, empty vector
controls (EV) were generated in parallel (Figure 1).
Then, the various cell lines were screened for stem
cell activity, using the mammosphere assay as a functional
readout. Importantly, Figure 2A directly validates that
over-expression of either WNT1 or FGF3 is sufficient
to increase the clonal expansion of cancer stem cells.
Interestingly, FGF3 and WNT1 significantly increased
mammosphere formation by ~1.5-fold and ~2.5-fold,

Figure 2: Recombinant over-expression of WNT1 and/or FGF3 in MCF7 cells significantly augments mammosphere
formation. A) Mammosphere formation. The cell lines we generated were screened for stem cell activity, using the mammosphere assay

as a functional readout. Note that over-expression of either WNT1 or FGF3 significantly increased mammosphere formation by ~1.5-fold
and ~2.5-fold, respectively. However, MCF7 cells over-expressing both WNT1 and FGF3 showed the largest increase in mammosphere
formation, by up to ~3.5-fold. Results were normalized to the three control cell lines harboring either i) EX-Neg-Lv105(puro), ii) EXNeg-Lv151(neo) or iii) both control vectors. P-values are as indicated. Assays were performed in triplicate and repeated three times
independently. MFE, mammosphere forming efficiency. B) Immunoblot analysis. Recombinant over-expression of WNT1 and FGF3 in
these transfected cell models was validated by immunoblot analysis, with specific antibody probes. Beta-actin is shown as a control for
equal loading.
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respectively. However, MCF7 cells over-expressing
both WNT1 and FGF3 showed the largest increase in
mammosphere formation, by up to ~3.5-fold (Figure 2A).
We also validated the recombinant over-expression
of WNT1 and FGF3 in these transfected cell models
by immunoblot analysis, with specific antibody probes
(Figure 2B).

(Right)).

Conditioned media from MCF7-WNT1/FGF3
cells is sufficient to increase mammosphere
formation.

To better understand how WNT and FGF signaling
drive the expansion of CSCs, we used unbiased label-free
proteomics analysis. The proteome of MCF7-WNT1/
FGF3 cells was compared to MCF7-EV control cells. We
restricted our analysis to protein products that were overexpressed by >1.5-fold. Overall, our results are detailed in
Tables 2, 3 and 4.
Remarkably, >40 nuclear-encoded mitochondrialrelated proteins were over-expressed in MCF7-WNT1/
FGF3 cells (Table 2). Many of these proteins were related
to the TCA cycle (ACO2), oxidative phosphorylation (MTCO2), regenerating ATP (CKMT1/2) or mitochondrial
biogenesis (TOMM34). In addition, MT-CO2 (a
mitochondria-DNA encoded protein) was upregulated
by >2.5-fold, indicative of the production of new
mitochondria. In support of an anabolic phenotype,
proteins related to glycolysis, the pentose phosphate
pathway, glycogen metabolism and amino acid synthesis
were upregulated (Table 2).

Proteomics analysis of MCF7-WNT1/FGF3
cells reveals the upregulation of EMT markers,
mitochondrial proteins, glycolytic enzymes, and
the protein synthesis machinery.

As WNT1 and FGF3 are secreted factors, it would
be predicted that the increase in constitutive stem cell
signaling could also act in a paracrine fashion on nontransfected cells. To test this hypothesis, we prepared
conditioned media from MCF7-WNT1/FGF3 cells and
the corresponding empty vector (MCF7-EV) control cells.
Then, we compared the ability of conditioned media
to support mammosphere formation, in untransfected
parental MCF7 cells. Figure 3 (Left) shows that
conditioned media prepared from MCF7-WNT1/FGF3
cells significantly stimulated mammosphere formation
by ~2-fold. Importantly, virtually identical results were
obtained with untransfected parental T47D cells, a second
independent ER(+) breast cancer cell line (Figure 3

Figure 3: Conditioned media from WNT1/FGF3 expressing MCF7 cells increases mammosphere formation. Since

WNT1 and FGF3 are secreted factors, they should act in a paracrine fashion on non-transfected cells. To test this hypothesis, we prepared
conditioned media from MCF7-WNT1/FGF3 cells and the corresponding empty vector (MCF7-EV) control cells. Then, we compared
the ability of this conditioned media to support mammosphere formation, in untransfected parental MCF7 cells (Left panel). Note that
conditioned media prepared from MCF7-WNT1/FGF3 cells significantly stimulated mammosphere formation by ~2-fold. Nearly identical
results were obtained with untransfected parental T47D cells, a second independent ER(+) breast cancer line (Right panel). Assays were
performed in triplicate and repeated three times independently. MFE, mammosphere forming efficiency.
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Stem-like cancer cells also undergo an epithelialmesenchymal transition (EMT), which promotes
cell migration, invasion and distant metastasis [23].
Importantly, >45 proteins known to be associated with
the EMT phenotype (cell migration or invasiveness)
were upregulated in MCF7-WNT1/FGF3 cells (Table 3).
www.impactjournals.com/oncotarget

Examples include FRS2 (FGF receptor substrate-2; >10fold) and β-catenin (>2-fold), which would be expected to
further amplify WNT/FGF signaling, as these are downstream elements of these convergent signaling networks.
Similarly, other signaling molecules that promote the EMT
and cell migration were significantly upregulated, such as
30457
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Expression of WNT1/FGF3-related targets in
patient-derived human breast cancer samples

MARCKS (>370-fold) and CDC42 (>65-fold).
Finally, augmented protein synthesis is another
characteristic of anabolic CSCs. Note that MCF7-WNT1/
FGF3 cells show the upregulation of >35 proteins related
to protein synthesis (Table 4). Examples include ribosomerelated proteins (RPS and RPL), translation initiation
factors (EIFs), peptide elongation factors (EEFs), enzymes
for tRNA synthesis, as well as chaperones for protein
folding (HSPs) and amino acid transporters (SLC).
Thus, MCF7-WNT1/FGF3 cells upregulate greater
than 140 proteins that would be consistent with an overall
anabolic phenotype (Figure 4).

www.impactjournals.com/oncotarget

To determine the possible translational significance
of our results, we intersected our WNT-FGF proteomics
data with human genome-wide transcriptional profiling
data. These human clinical data were derived from
publically available human breast cancer samples, in
which breast cancer cells were separated by laser-capture
microdissection from tumor stromal cells. Transcriptional
profiles were analyzed from from N=28 human breast
cancer patients (See the Materials & Methods section). In
this data set, gene expression was previously determined
30459
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MCF7-WNT1/FGF3 cells show a functional
increase in mitochondrial mass and mitochondrial
membrane potential

using Affymetrix U133A 2.0 GeneChips. A concise
summary of these findings is presented in Tables 5, 6
and 7. Overall, greater than sixty WNT1/FGF3 targets
(related to mitochondria, glycolysis, the EMT, and protein
synthesis) that we identified in MCF7-WNT1/FGF3 cells
were also transcriptionally elevated in human breast
cancer cells in vivo. These new protein targets that we
identified in MCF7-WNT1/FGF3 cells may be important
for developing new strategies for the diagnosis and
treatment of breast cancer.

To further validate the mitochondrial phenotype of
MCF7-WNT1/FGF3 cells, we used fluorescent probes
to quantitate mitochondrial mass and mitochondrial
membrane potential by FACS analysis. For this purpose,
we used MitoTracker Deep-Red (640-nm) to measure
mitochondrial mass and MitoTracker Orange (561-nm),
as a measure of mitochondrial membrane potential.
Figure 5 (Left panels) show that as compared to
EV control MCF7 cells, MCF7 cells overexpressing
WNT1/FGF3 show a clear shift to the right, for both
mitochondrial mass and membrane potential. Furthermore,
quantitation of fluorescence intensity (MFI) reveals that
both of these mitochondrial parameters are significantly
elevated in MCF7-WNT1/FGF3 cells (Figure 5 (Right
panels)).
These results suggest that increased mitochondrial
mass and function may be important features of the
anabolic CSC phenotype.

High mitochondrial mass is a key determinant
of mammosphere-forming activity in parental
MCF7 cells
Based on our above observations with WNT1/
FGF3 signaling, we would predict that mitochondrial
biogenesis is critical for mammosphere forming activity.
To test this hypothesis more directly, we metabolically
fractionated untransfected parental MCF7 cells, using
MitoTracker Deep-Red, as a measure of mitochondrial
mass. In this context, we chose to analyze three distinct
metabolic phenotypic sub-groups: i) negative cells (little
or no positive staining; mito-negative group); ii) bottom
5% (mito-low group); and top 5% (mito-high group). Only
live cells in each group were selected for this analysis.
Five thousand live cells from each group were
then seeded per well, in 6-well low attachment plates, to
measure mammosphere-forming efficiency. Remarkably,
Figures 6 and 7 directly show that increasing mitochondrial
mass results in a 3.0 to 5.5-fold increase in mammosphereforming activity, depending on which gating parameters
are used (singlet-gating vs. all live cells). A comparison
with all live cells is also shown because mammary stem
cells tend to be larger than non-stem cells (See Ref # 37
for a discussion of this point).
As such, the mito-negative group showed the
least 3-D sphere-forming activity, while the mito-high
group showed the highest 3-D sphere-forming efficiency.
Thus, we conclude that mitochondrial mass can be
used to enrich for stem-like cancer cells that are able to
undergo anchorage-independent propagation, under lowattachment conditions.

Figure 4: The anabolic CSC phenotype: Proteomics
analysis. Unbiased label-free proteomics analysis of MCF7-

WNT1/FGF3 cells revealed the induction of i) mitochondrial
proteins, ii) glycolytic enzymes, iii) protein synthesis
machinery and iv) EMT markers, consistent with an anabolic
CSC phenotype. For specific details, see Tables 2, 3 and 4.
Mitochondrial proteins – Greater than 40 nuclear-encoded
mitochondrial-related proteins were over-expressed in MCF7WNT1/FGF3 cells. Many of these proteins were related to the
TCA cycle (ACO2), oxidative phosphorylation (MT-CO2),
regenerating ATP (CKMT1/2) or mitochondrial biogenesis
(TOMM34). In addition, MT-CO2 (a mitochondrial DNA
encoded protein) was upregulated by >2.5-fold. Glycolytic
enzymes – More than 10 enzymes related to glycolysis, the
pentose phosphate pathway, glycogen metabolism and amino
acid synthesis were all upregulated in MCF7-WNT1/FGF3
cells. Protein synthesis machinery – Over 35 proteins related to
protein synthesis, including ribosome-related proteins, enzymes
for tRNA synthesis, chaperones for protein folding and amino
acid transporters, were all up upregulated in MCF7-WNT1/
FGF3 cells. EMT markers – Greater than 45 proteins known
to be associated with the EMT phenotype were upregulated
in MCF7-WNT1/FGF3 cells. Examples include FRS2 (FGF
receptor substrate-2; >10-fold) and β-catenin (>2-fold).
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Discussion

mitochondrial function were validated by MitoTracker
staining. Proteins up-regulated by WNT/FGF-signaling
in MCF7 cells, were also transcriptionally over-expressed
in breast cancer cells in vivo, based on the bioinformatic
analysis of public datasets of laser-captured epithelial
tumor cells from breast cancer patients. We believe that
this isogenic cell model will accelerate the identification
of new protein biomarkers to predict clinical outcomes
in breast cancer patients. Remarkably, metabolic
fractionation of parental MCF7 cells, via MitoTracker
staining, indicated that mitochondrial mass is a key
determinant of mammosphere-forming activity. The mitonegative group showed the least sphere-forming activity,
while the mito-high group showed the highest sphereforming efficiency. Thus, new mitochondrial biogenesis is
critical for the successful propagation of stem-like cancer
cells.

The mouse mammary tumor virus (MMTV)
initiates mammary tumorigenesis in mice by promoter
insertion adjacent to two main integration sites, namely
Int-1 (Wnt1) and Int-2 (Fgf3), driving the propagation
of mammary cancer stem cells [11-13, 20]. Here, we
developed an isogenic cell model of MMTV signaling
to facilitate protein biomarker discovery in breast
cancer (Figure 8). More specifically, we over-expressed
WNT1 and FGF3 in MCF7 cells, an ER(+) human
breast cancer cell line. Importantly, MCF7 cells overexpressing both WNT1 and FGF3 showed a 3.5-fold
increase in mammosphere formation. Proteomic analysis
of this model system revealed the induction of EMT
markers, mitochondrial proteins, glycolytic enzymes and
protein synthesis machinery, consistent with an anabolic
phenotype. The WNT1/FGF3-induced increases in

Figure 5: WNT1/FGF3 over-expressing MCF7 cells have increased mitochondrial mass and activity. We used two different

fluorescent probes to quantitate mitochondrial mass and mitochondrial membrane potential by FACS analysis. Briefly, we employed
MitoTracker Deep-Red (640-nm) to measure mitochondrial mass and MitoTracker Orange (561-nm), as a measure of mitochondrial
membrane potential. Note that as compared to EV control MCF7 cells, MCF7 cells overexpressing WNT1/FGF3 show a clear shift to the
right, for both mitochondrial mass (Lower panels) and membrane potential (Upper panels). Quantitation of fluorescence intensity (MFI)
reveals that both of these mitochondrial parameters are significantly elevated in MCF7-WNT1/FGF3 cells. P-values are as shown. These
results suggest that both mitochondrial mass and function may be critical features of the CSC phenotype.
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Figure 6: Metabolic fractionation of parental MCF7 cells directly correlates with mammosphere-forming activity:
Gating for singlet cells. We metabolically fractionated parental MCF7 cells, using MitoTracker Deep-Red, as a measure of mitochondrial

mass. In this context, we chose to analyze three distinct metabolic phenotypic groups: i) negative cells (little or no positive staining; mitonegative group); ii) bottom 5% (mito-low group); and top 5% (mito-high group). Only live cells in each group were selected for this
analysis. Five thousand live cells from each group were then seeded per well, in 6-well low attachment plates, to measure mammosphereforming efficiency. Note that increasing mitochondrial mass results in a 3.0-fold increase in mammosphere-forming activity. Thus, the
mito-deficient group showed the least sphere-forming activity, while the mito-high group showed the highest sphere-forming efficiency.
Assays were performed in triplicate and repeated three times independently. The mean number of mammospheres (3-D spheroids) formed
is shown.
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Figure 7: Metabolic fractionation of parental MCF7 cells directly correlates with mammosphere-forming activity:
Gating for all live cells. As in Figure 6, except that FACS gating included all live cells, not only live singlets. Under these conditions,

note that increasing mitochondrial mass results in a >5.5-fold increase in mammosphere-forming activity. Assays were performed in
triplicate and repeated three times independently. The mean number of mammospheres (3-D spheroids) formed is shown.
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Figure 8: Anabolic CSC signaling: Exploiting a
humanized model of MMTV signaling to identify the
characteristics of anabolic CSCs and achieve the goals
of personalized medicine. A humanized isogenic model of

MMTV-signaling was generated by co-expressing WNT1 and
FGF3 in MCF7 cells, an ER(+) human breast cancer cell line.
This model was first validated using the mammosphere assay to
measure stem cell activity and then subjected to unbiased labelfree proteomics analysis. WNT1/FGF3 protein targets identified
in this manner were found to be transcriptionally over-expressed
in human breast cancer cells in vivo, providing clinical validation
of the success of our approach. Thus, we established that the
anabolic CSC phenotype is characterized by the induction of
EMT markers, mitochondrial proteins, glycolytic enzymes and
protein synthesis machinery. These represent new classes of
identified protein targets for drug discovery and the identification
of companion diagnostics, to eradicate anabolic CSCs.
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Role of new mitochondrial biogenesis in WNTsignaling and asymmetric cell division in stem
cells

on down-stream effectors, such as IRS-1 and c-MYC
[24]. Therefore, the effects of WNT/β-catenin signaling
on mitochondrial biogenesis, may ultimately be mediated
by the c-MYC proto-oncogene.
Asymmetric cell division is required for the
maintenance of the stem cell phenotype and also occurs
in stem-like cancer cells. Recently, Weinberg and Sabatini
assessed how mitochondria are apportioned during
asymmetric cell division, using an immortalized model
of mammary epithelial stem cells [26]. Interestingly,
they observed that “newly-synthesized” mitochondria
were concentrated in stem cells during asymmetric cell
division, while “old” mitochondria were segregated into
daughter cells. As such, asymmetric cell division requires
new mitochondrial biogenesis, for the propagation the
stem cell phenotype. These findings could mechanistically
explain our current results, that high-mitochondrial mass
(Figures 6 and 7) directly correlates with “stemness” and
mammosphere-forming efficiency.

Interestingly, two previous studies have also linked
WNT signaling to new mitochondrial biogenesis, in
the context of skeletal muscle function and osteoblastic
differentiation [24, 25]. For example, Yoon et al performed
an si-RNA screen to identify novel protein targets that are
critical for driving mitochondrial biogenesis in skeletal
muscle cells [24]. For this purpose, they screened the
effects of si-RNAs on C2C12 cells, representing >6,300
genes, using a high-throughput FACS-based assay to
measure mitochondrial function. Overall, they identified
>150 proteins not previously recognized to be involved in
the regulation of mitochondrial biogenesis. Bioinformatics
analysis of this data set identified WNT/β-catenin signaling
as a key regulator of mitochondrial biogenesis. This
was functionally validated by using si-RNAs targeting
β-catenin and Axin2. Moreover, treatment of C2C12
cells with Wnt3a increased mitochondrial biogenesis
by nearly 2-fold, which also directly correlated with a
functional increase in oxygen consumption. Expression
of a dominant-negative form of TCF4 blocked the effects
of Wnt3a on mitochondrial biogenesis, indicating that
the canonical Wnt-pathway was responsible for the
metabolic effects of Wnt3a. Interestingly, Wnt3a mediated
mitochondrial biogenesis also appeared to be dependent

Role of mitochondrial biogenesis in anchorageindependent growth, in transformed fibroblasts
and CSCs
In 1984, Klebe and Harriss described the use
of a colorimetric tetrazolium dye, namely MTT, to
distinguish between normal and transformed fibroblasts,
when the two different immortal isogenic cell lines
were co-cultured [27]. More specifically, they showed
that SV40-transformed BALB/3T3 fibroblasts, which
were undergoing anchorage-independent growth (fociformation), were highly MTT-positive [27]. In contrast,
non-transformed quiescent BALB/3T3 cells were MTTnegative, showing little or no staining [27]. As MTTstaining has largely been attributed to mitochondrial
oxidative function and redox activity, these results may be
the first description of an association between anchorageindependent growth and mitochondrial function.
In accordance with these findings, Fisher et al.,
2011 [28] demonstrated that PGC1-α mediated activation
of mitochondrial biogenesis is indeed required for the
anchorage-independent growth of RAS-transformed
fibroblasts. Moreover, recent studies with XCT790,
a chemical inhibitor of the ERR-α/PGC1-α signaling
network, directly showed that blocking mitochondrial
biogenesis is sufficient to effectively prevent the
anchorage-independent survival and propagation of
epithelial CSCs [29]. Quantitatively similar results were
also obtained with azithromycin and doxycycline [29, 31],
two well-established antibiotic inhibitors of mitochondrial
biogenesis, which target mitochondrial protein translation.
Thus, our current results are also consistent with
the idea that mitochondrial power somehow helps to
energize anchorage-independent growth, which is a key
characteristic of CSCs.

Figure 9: Convergent role of energy metabolism in the
pathogenesis of viral oncogenesis, driven by promoter
insertion: A new metabolic hypothesis. We propose that

MMTV and ALV may induce oncogenesis by a convergent
metabolic mechanism, which relies on an anabolic CSC
phenotype, characterized by increased mitochondrial biogenesis
and augmented protein synthesis. See the Discussion section
for further details. ALV, avian leukosis virus; MMTV, mouse
mammary tumor virus.
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specifically, they observed that both of these parameters
increased by up to 2 to 3 fold, when normal endometrial
tissue was directly compared to endometrial cancer [38].
Similarly, they also observed that the protein expression
levels of three mitochondrial-related transcription factors
(TFAM, NRF1 and PGC1-alpha) were all significantly
increased by nearly 2-fold [39]. Taken together, these
results are all consistent with an increase in mitochondrial
biogenesis, during the pathogenesis of tumor initiation.
Similarly, we have previously shown that markers
of mitochondrial mass and mitochondrial activity are
specifically localized to the basal stem cell layer in
normal human mucosa, which co-localizes with Ki67, an
established marker of cell proliferation [40]. In addition,
this mitochondria-rich population of cells is dramatically
expanded in head and neck cancers [40] and breast
cancers [41-43]. Moreover, recombinant over-expression
of mitochondrial-related proteins, such as PGC1-alpha/
beta, POLRMT, MitoNEET or GOLPH3, is sufficient to
promote tumor growth, by up to 3-fold, in xenografted
pre-clinical models of human breast cancers [44, 45].
Finally, mitochondrial biogenesis and mass are also
significantly increased in hematological malignancies,
such as in chronic lymphocytic leukemia (CLL) and acute
myeloid leukemia (AML) [46-49].
This increase in mitochondrial mass also appears
to be part of a normal developmental process, as
mitochondrial biogenesis increases between 25 to 50
fold, during mammalian embryogenesis, especially from
the two-cell stage to the early blastocyst [50]. This early
stage of embryogenesis reflects the proliferative expansion
normal progenitor cells. Interestingly, pluripotent ES cell
lines are derived from the inner cell mass of the blastocyst.

MMTV is known to cause the development of
mammary tumors by promoter insertion proximal to
cellular proto-oncogenes, that when over-expressed,
confer an oncogenic phenotype. This appears to be largely
through the constitutive activation of WNT/β-catenin
signaling. Here, we show that this signal transduction
process also leads to the activation of mitochondrial
biogenesis and an increase in the machinery necessary
for protein synthesis, which is characteristic of an
anabolic CSC phenotype. Previous studies have also
shown that the ability of WNT/β-catenin signaling
to increase mitochondrial biogenesis is dependent on
c-MYC activation, but in the context of skeletal muscle
cells [24]. In further support of these ideas, MMTV Int-6
is eukaryotic translation initiation factor 3 (eIF3), which
serves as a scaffolding protein to increase protein synthesis
(Table 1).
Avian leukosis virus (ALV) is another pathogen that
induces cancer, via a promoter insertion-based mechanism
[32, 33]. More specifically, ALV infection leads to
proviral intergration and promoter insertion, driving the
development of myeloid leukosis and, ultimately, frank
leukemia in chickens. Interestingly, the most common
ALV integration sites include c-MYC and hTERT, as well
as other gene products related to mitochondrial biogenesis
and function (NDUFS6 and PARK2) [34].
Taken together, these data imply that MMTV and
ALV may induce oncogenesis by a convergent metabolic
mechanism, which relies on the down-stream activation
of c-MYC, driving increased mitochondrial biogenesis.
Interestingly, c-MYC is also known to increase protein
synthesis, by targeting translation initiation, as well as by
directly increasing ribosomal biogenesis [35, 36]. As such,
MMTV and ALV may both ultimately induce the anabolic
CSC phenotype, via increased mitochondrial biogenesis
and increased protein synthesis (Figure 9). In further
support of this idea, hTERT over-expression also appears
to be directly associated with an anabolic CSC phenotype,
driving increased mitochondrial biogenesis and augmented
protein synthesis [37]. Thus, this intriguing hypothesis,
regarding the existence of a convergent metabolic
mechanism, underlying MMTV and ALV oncogenesis,
undoubtedly deserves further study.

Conclusions
In summary, the use of mitochondrial mass as
a surrogate metabolic biomarker of mitochondrial
biogenesis allows for the identification of stem-like cancer
cells, facilitating CSC enrichment for future biomarker
studies and aiding in the design of novel therapeutic
interventions. In this context, MCF7 cells over-expressing
WNT1/FGF3 will provide a novel model system for these
ongoing investigations.

Materials and Methods

Mitochondrial DNA content and mitochondrial
mass both increase during the transition from
normal tissue to hyperplasia and malignancy

Materials
Breast cancer cell lines (MCF7 and T47D) were
originally purchased from the ATCC. Gibco-brand cell
culture media (DMEM and DMEM/F12) was purchased
from Life Technologies. Lentiviral vectors encoding
WNT1 [EX-B0110-Lv105(puro)] and FGF3 [EX-

Interestingly, previous studies in human endometrial
cancer have monitored i) mt-DNA content (by RT-PCR)
and ii) mitochondrial mass (using the enzyme activity of
citrate synthase), during the transition to malignancy. More
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A0154-Lv151(neo)] were obtained commercially from
Genecopoeia (USA), along with appropriate empty vector
controls [EX-Neg-Lv105(puro) and EX-Neg-Lv151(neo)].
Antibodies directed against FGF3 (# HPA012692, Sigma)
and WNT1 (# ab15251, Abcam) were also obtained
commercially. MitoTracker probes (Deep-Red and
Orange) were purchased from Molecular Probes, via Life
Technologies.

at a density of 500 cells/cm2 in mammosphere medium in
culture dishes coated with poly-HEMA (Sigma, #P3932).
After 5 days, 3D spheroids with a diameter greater than
50 µm were counted using a microscope, fitted with a
graticule eye-piece, and the percentage of cells which
formed spheroids was calculated and normalized to one
(1 = 100 % MSE; mammosphere forming efficiency).
Mammosphere assays were performed in triplicate and
repeated three times independently.

MCF7 cell viral transduction and antibiotic
selection

Conditioned media experiments

Lentiviral particles harboring human WNT1 [EXB0110-Lv105(puro)] or human FGF3 [EX-A0154Lv151(neo)] were prepared and used to stably transduce
MCF7 cells, according to the manufacturer’s protocol.
After 24 hours, media containing the virus was removed
and replaced with standard media. Cells were then
selected with puromycin (2 μg/ml) or G418 (2 mg/ml),
for up to 10 days. MCF7 cells harboring the empty vector
alone controls were generated at the same time in parallel.
MCF7-WNT1/FGF3 cells were generated by serial
transduction with both WNT1 and FGF3 lentiviral vectors.

One million MCF7 cells transfected with WNT1/
FGF3 or empty vector alone controls were plated for 24
hours in DMEM (10% FCS). Cells were then washed
in PBS, the subsequently cultured for 72 hours in 10 ml
of DMEM/F12 phenol-red free media (mammosphere
media). Media was then collected and cells were removed
by centrifugation at 1800 rpm for 10 minutes. Conditioned
media was then added directly to mammosphere assays
of parental untransfected breast cancer cell lines (MCF7
and T47D) in a ratio of 1:1 with fresh mammosphere
formation media.

WNT1 and FGF3 immunoblotting

Unbiased label-free proteomics analysis

Transduced MCF7 cells were seeded in 10 cm
dishes for 72 hrs. Then, cells were lysed in RIPA buffer
(Sigma), containing proteinase inhibitors (Roche) and
kept at 4°C for 30 minutes. Lysates were collected by
centrifugation for 10 minutes at 10,000 x g, and protein
concentration were determined using the BCA protein
assay kit (Pierce). Samples were diluted into SDS-PAGE
sample buffer and were boiled for 5 minutes before
being separated by SDS-PAGE, using a 4-15% gradient
Mini-PROTEAN TGX Gel (Biorad). Samples were then
transferred onto a nitrocellulose membrane (Biorad),
blocked in 5% milk in TBS-Tween 20 (Sigma) and
probed with antibodies directed against WNT1 or FGF3
and β-actin (Santa Cruz Biotechnology, #sc-1616), using
a secondary antibody at a dilution of 1 to 5000. Bound
antibodies were detected using the Supersignal West
Pico Chemiluminiscent substrate (ThermoScientific).
Alternatively, in the laboratory, blots were also routinely
processed with a blocking solution containing BSA, as a
blocking agent. Similarly, other comparable antibodies
directed against β-actin were used, but were obtained from
different commercial sources, such as Sigma.

Proteomics analysis was carried out essentially as
we previously described, with minor modifications [52,
53]. Statistical analyses were performed using ANOVA
and only fold-changes in proteins with a p-value less than
0.05 were considered significant. Unbiased proteomics and
the statistical analysis of the results were performed by the
Biological Mass Spectrometry Core Facility, at the Cancer
Research UK Manchester Institute, under the supervision
of Dr. Duncan L. Smith.

Bioinformatics analysis with publically available
human breast cancer clinical data
To determine the possible translational significance
of our proteomics analysis, we intersected our MCFbased WNT/FGF proteomics data with human genomewide transcriptional profiling data. These human clinical
data were derived from publically available human
breast cancer samples, in which breast cancer cells were
separated by laser-capture microdissection from tumor
stromal cells. Transcriptional profiles were analyzed from
N=28 human breast cancer patients [54].

Assessment of mammosphere forming activity

Analysis of mitochondrial mass and membrane
potential

Mammosphere formation was carried out, essentially
as described previously by Clarke and colleagues, without
any significant modifications [51]. MCF7 cells were plated
www.impactjournals.com/oncotarget

To measure mitochondrial activity, cells were
stained with MitoTracker Orange (#M7510, Invitrogen),
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whose accumulation in mitochondria is dependent upon
membrane potential. To measure mitochondrial mass,
cells were stained with MitoTracker Deep Red (#M22426,
Invitrogen), localizing to mitochondria regardless of
mitochondrial membrane potential. Cells were incubated
with pre-warmed MitoTracker staining solution (diluted
in PBS/CM to a final concentration of 10 nM) for 30-60
min at 37 °C. All subsequent steps were performed in
the dark. Cells were washed in PBS, harvested, and resuspended in 300 μL of PBS. Cells were then analyzed
by flow cytometry. Data analysis was performed using
FlowJo software.
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Using MitoTracker Deep-Red staining as a marker
of mitochondrial mass, we metabolically fractionated
parental MCF7 cells, using FACS analysis and cell
collection. In these experiments, we analyzed three
different metabolic sub-groups: i) negative cells (little or
no positive staining; mito-negative group); ii) bottom 5%
(mito-low group); and top 5% (mito-high group). Only
live cells in each group were selected for this analysis.
Five thousand live cells from each group (performed
in triplicate) were then seeded per well, in 6-well low
attachment plates, to measure mammosphere-forming
efficiency. Gating for cell size was varied to take into
account the observation that stem-like mammary cells
may be physically larger than “bulk” cancer cells, as was
previously suggested.
This method is a further refinement of a protocol
used by Farnie, Sotgia and Lisanti, in a companion study
published in parallel [55]. Importantly, very similar
results were obtained here, indicating that the method is
operator independent. For example, see Figure 4 (Panel
A) in Farnie et al., 2015, for comparison purposes [55];
however, in this companion paper, the mito-negative group
was not analyzed.
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